Cipla Ltd · NSE:CIPLA
Cipla — Q2 FY2025 Earnings Presentation
16 slides from Cipla's earnings presentation, Oct 29, 2024
Slide 1: Exchange filing cover letter: Investor Presentation
29th October, 2024 (1) BSE Ltd. (2) National Stock Exchange of India Ltd. Listing Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor Dalal Street Plot no. C/1, G Block Mumbai 400 001 Bandra Kurla Complex Scrip Code: 500087 Bandra (East), Mumbai - 400 051 Scrip Code: CI
Slide 2: Investor Presentation Q2FY25
Investor Presentation Q2FY25 29-10-2024 1
Slide 3: Disclaimer
DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 4: Upward operating profitability trajectory sustained
Upward operating profitability trajectory sustained1 Revenue EBITDA PAT 12% (YoY) 17% (YoY) 9% INR 1,886 Cr INR 1,303 Cr Q2FY25 INR 7,051 Cr (YoY) 70 bps 130 bps 26.7% 18.5% of Revenue of Revenue Business Performance Snapshot Emerging Markets & One India North America South Africa Private Europe INR
Slide 5: Financial Performance – Q2FY25
Financial Performance1 – Q2FY25 Revenues INR 7,051 Cr EBITDA INR 1,886 Cr Revenue2 Break-up Q2FY25 (Consolidated) API, 2% Others, 1% Actuals vs Q2 FY24 Emerging Markets & (INR Cr) Europe, 12% Total Revenue from 7,051 8.6% Operations EBITDA 1,886 11.6% One India, One Africa, 42% EBITDA % 26.7% 70 bps
Slide 6: One India: Driving long-term growth with a legacy of sustainability
One India1 : Driving long-term growth with a legacy of sustainability One India revenue trend India Rx revenue trend TTM Sep-21 TTM Sep-24 TTM Sep-21 TTM Sep-24 INR 8,166 Cr INR 11,123 Cr INR 6,148 Cr INR 8,505 Cr CAGR2 CAGR2 11% 11% Branded Prescription Trade Generics Consumer Health ❖ Cipla mainta
Slide 7: India Branded Prescription – Progressing on our journey by focused approach
India Branded Prescription – Progressing on our journey by focused approach Steady uptake in key therapies1 growth (%) Rank 1.8 (12.2%)2 Largest pharma company by Volume Respiratory 1st Slow industry 8.5 (15.3%) 2 (units) in IPM1 growth in 4.9 (12.0%) 2 Respiratory and Anti-infectives 4th 5.2 (9.0%)
Slide 8: H1FY25: Global Consumer Wellness Franchise demonstrating promising outcomes
H1FY25: Global Consumer Wellness Franchise demonstrating promising outcomes One India : Revenue INR 748 Cr 2 2 1 2 2 Pain relief Hydration Nicotine Replacement Skin infection Cold & cough INR 135+ Cr INR 115+ Cr INR 85+ Cr INR 60+ Cr INR 40+ Cr South Africa : Revenue ZAR 830 Mn Cough, cold & flu Cou
Slide 9: North America: Consistent revenue trajectory backed by traction in key assets
North America: Consistent revenue trajectory backed by traction in key assets $ Mn 250 229 230 226 237 222 195 204 179 155 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Key Business Highlights • 4 new generic drug approvals during the quarter: Calcitonin Salmon Injectable, Di
Slide 10: ANDA & NDA Portfolio & Pipeline (As on 30th Sep 2024)
ANDA & NDA Portfolio & Pipeline (As on 30th Sep 2024) 8 66 9 3 16 8 85 2 2 55 18 8 Approved Tentatively Under Approval ANDAs & NDAs Approved ANDAs & NDAs ANDAs & NDAs Cipla Ltd PEPFAR 1 Invagen Partnered ANDAs/NDAs 168 30 82 280 Approved Tentatively Under Approval Total ANDAs & NDAs Approved ANDAs &
Slide 11: One Africa: Further strengthening our Africa story by integrating North Africa
One Africa1: Further strengthening our Africa story by integrating North Africa ZAR Mn $ Mn SA Private Revenue trend One Africa Revenue 127 104 23 1,341 22 22% 9 7 20 1,197 11 1,065 64 75 Q2FY24 Q2FY25 Q2FY23 Q2FY24 Q2FY25 SA Private SA Tender North Africa Others (SSA & CGA) Healthy performance acro
Slide 12: Q2FY25: Emerging Markets & Europe and API
Q2FY25 : Emerging Markets & Europe and API Emerging Markets & Europe1 API $ Mn Revenue $ Mn Revenue 96 19 18 82 18% 7% Q2FY24 Q2FY25 Q2FY24 Q2FY25 1. North Africa region is reclassified from Emerging Markets to One Africa. 11
Slide 13: Progress on 2025 Environmental, Social & Governance goals
Progress on 2025 Environmental, Social & Governance goals CLICK TO EDIT MASTER TITLE STYLE Progress on ESG – YTM Aug’ 24 Businessworld India’s Most Sustainable Companies Award Cipla achieved 100 percentile in the S&P DJSI Global CSA 2024, with the score rising to 79 from 70 in 2023 100 MWp Solar pro
Slide 14: Profit and Loss statement summary (Reported)
Profit and Loss statement summary (Reported) INR Cr Particulars Q2 FY25 Q2 FY24 Revenue from sale of products 6,961 6,589 Other operating income 90 89 Income from operations 7,051 6,678 Material cost 2,283 2,313 Employee benefits expense 1,208 1,091 Other expenses 1,675 1,540 Total expenses 5,165 4,
Slide 15: Balance Sheet (Reported)
Balance Sheet (Reported) INR Cr Key Balance Sheet Items Sep-24 Jun-24 Mar-24 Equity 28,456 28,058 26,802 Total Debt 461 547 559 Inventory 5,573 5,531 5,238 Cash and Cash Equivalents* 8,412 8,996 8,267 Trade Receivables 5,588 4,990 4,771 Trade Payables 2,675 2,742 2,474 Net Tangible Assets 6,329 6,21
Slide 16: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Diksha Maheshwari Investor.Relations@cipla.com For more information please visit www.cipla.com 15